Sorrento Therapeutics (SRNE) versus Its Rivals Financial Survey

Sorrento Therapeutics (NASDAQ: SRNE) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Sorrento Therapeutics to similar businesses based on the strength of its valuation, dividends, risk, profitability, institutional ownership, analyst recommendations and earnings.

Volatility & Risk

Sorrento Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics’ rivals have a beta of 6.66, indicating that their average share price is 566% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sorrento Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Sorrento Therapeutics $15.80 million -$69.49 million -3.63
Sorrento Therapeutics Competitors $263.26 million $68.25 million -6.44

Sorrento Therapeutics’ rivals have higher revenue and earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

15.8% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.0% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sorrento Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sorrento Therapeutics -257.81% -95.98% -21.59%
Sorrento Therapeutics Competitors -5,458.35% -450.70% -43.40%

Analyst Ratings

This is a breakdown of current recommendations for Sorrento Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sorrento Therapeutics 0 0 5 0 3.00
Sorrento Therapeutics Competitors 767 3061 11246 227 2.71

Sorrento Therapeutics presently has a consensus target price of $12.60, indicating a potential upside of 375.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.67%. Given Sorrento Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Sorrento Therapeutics is more favorable than its rivals.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

What are top analysts saying about Sorrento Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sorrento Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit